Cardiovascular effects of octreotide, a long-acting somatostatin analog

Cardiovascular Drug Reviews

Volumn 17, Issue 4, 1999, Pages 358-373

  Sakamoto, Hironosuke ^a,b  

^a GUNMA UNIVERSITY   (Japan)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiovascular disease; Octreotide; SMS 201 995; Somatostatin analog

Indexed keywords

OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EFFECT; DRUG HALF LIFE; DRUG INDICATION; DRUG RESEARCH; DRUG STRUCTURE; GASTROINTESTINAL TRACT; HUMAN; HYPOPHYSIS; KIDNEY FUNCTION; LUNG FUNCTION; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0033509612     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1999.tb00025.x     Document Type: Review

References (61)

1. Albat B, Leclercq FF, Serre I, et al. Heart transplantation for terminal congestive heart failure in an acromegalic patient. Eur Heart J 1993;14:1572-1575.
2. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;6:369-375.
3. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-1140.
4. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;173:77-79.
5. Buscail L, Delesque N, Esteve J-P, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 1994;91:2315-2319.
6. 2 in conscious dogs. Eur Respir J 1988;11:1376-1381.
7. Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990;113:921-925.
8. Cohen P. Signal integration at the level of protein kinases, protein phosphatases, and their substrates. Trends Biochem Sci 1992;17:408-413.
9. Colao A, Cuocolo A, Marzullo P, et al. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999;84:17-23.
10. Cool DE, Andreassen PR, Tonks NK, Krebs EG, Fischer FH, Morgolis RL. Cytokinetic failure and asynchronous nuclear division in BHK cells overexpressing a truncated protein-tyrosine-phosphatase. Proc Natl Acad Sci USA. 1992;89:5422-5426.
11. del Pozo E, Neufeld M, Schluter K, et al. Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol 1986;111: 433-439.
12. Demirtas E, Sag C, Kursaklioglu H, et al. Effects of octreotide in patients with hypertrophic obstructive cardiomyopathy. Jpn Heart J 1998;39:173-181.
13. Fallo F, Barzon L, Boscaro M, Casiglia E, Sonino N. Effect of octreotide on 24-h blood pressure profile in acromegaly. Am J Hypertens 1998;11:591-596.
14. Filuk RB, Berezanski DJ, Anthonisen NR. Depression of hypoxic ventilatory response in humans by somatostatin. J Appl Physiol 1988;65:1050-1054.
15. Flogstad AK, Halse J, Haldorsen T, et al. Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 1995;80:3601-3607.
16. Fuessl HS, Burrin JM, Williams G, Adrian TE, Bloom SR. The effect of a long-acting somatostatin analogue (SMS 201-995) on intermediary metabolism and gut hormones after a test meal in normal subjects. Aliment Pharmacol Ther 1987;1:321-330.
17. Gaudin C, Moreau R, Champigneulle B, Soubrane O, Kleber G, Lebrec D. Short-term cardiovascular effects of somatostatin in patients with cirrhosis. Liver 1995;15:236-241.
18. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). Drug 1997;53:681-699.
19. Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? Circulation 1994;89:1511-1517.
20. Grunstein RR, Ho KY, Berthon-Jones M, Stewart D, Sullivan CE. Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly. Am J Respir Crit Care Med 1994;150:496-502.
21. Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991;115:527-532.
22. Grunstein RR, Ho KY, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 1994;121:478-483.
23. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 1994;35(Suppl 3):S1-S4.
24. Hoeldtke RD, Davis KM, Joseph J, Gonzales R, Panidis IP, Friedman AC. Hemodynamic effects of octreotide in patients with autonomic neuropathy. Circulation 1991;84:168-176.
25. Hoeldtke RD, O'Dorisio TM, Boden G. Treatment of autonomic neuropathy with a somatostatin analogue SMS-201-995. Lancet 1986;2:602-605.
26. Ito H, Hiroe M, Hirata Y, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 1993;87:1715-1721.
27. Jones CR, Millar JA, Lawrie C, Summer DJ, Reid JL. Specific inhibition of aldosterone response to endogenous and exogenous angiotensin II by somatostatin. Clin Endocrinol 1984;21:279-284.
28. Kobayashi S, Nishimura M, Taguchi H, Miyamoto K, Kawakami Y. Effect of octreotide on ventilation and dyspnea sensation in a patient with cirrhotic hypoxemia. Intern Med 1995;34:401-405.
29. Kutz K, Nuesch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 1986;21(Suppl 119):65-72.
30. Lamberts SWJ, Oosterom R, Neufeld M, del Pozo E. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 1985;60:1161-1165.
31. Lemaire M, Azria M, Dannecker R, Marbach P, Schweitzer A, Maurer G. Disposition of sandostatin, a new synthetic somatostatin analogue, in rats. Drug Metab Dispos 1989;17:699-703.
32. Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic, and biliary function and hormone release in normal man. Digestion 1987;36:108-124.
33. Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypertension. Ann Intern Med 1992;117:719-726.
34. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991;68:106-113.
35. Liu MW, Roubin GS, King SB III. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 1989;79:1374-1387.
36. Londong W, Angerer M, Kutz K, Landgraf R, Londong V. Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration. Gastroenterology 1989; 96:713-722.
37. Malesci A, Tacconi M, Valentini A, Basilico M, Lorenzano E, Salerno F. Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function. J Hepatol 1997;26:816-825.
38. Maxwell DL, Chahal P, Nolop KB, Hughes JM. Somatostatin inhibits the ventilatory response to hypoxia in humans. J Appl Physiol 1986;60:997-1002.
39. McCormick PA, Chin J, Greenslade L, et al. Cardiovascular effects of octreotide in patients with hepatic cirrhosis. Hepalology 1995;21:1255-1260.
40. Mountokalakis T, Kallivretakis N, Mayopoulou-Symvoulidou D, Karvountzis G, Tolis G. Enhancement of renal function by a long acting somatostatin analogue in patients with decompensated cirrhosis. Nephrol Dial Transplant 1988;3:604-607.
41. Nobuyoshi M, Kimura T, Nosaka H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988;12:616-623.
42. Padayatty S, Perrins EJ, Belchetz PE. Octreotide treatment increases exercise capacity in patients with acromegaly. Eur J Endocrinol 1996;134:554-559.
43. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. Life Sci 1995;57:1249-1265.
44. Reichlin S. Somatostatin. N Engl J Med 1983;309:1495-1501, 1556-1563.
45. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocrine Rev 1995;16:427-442.
46. Reubi JC, Lamberts SWJ, Maurer R. Somatostatin receptors in normal and tumoral tissues. Horm Res 1988;29:65-69.
47. Reubi JC, Maurer R, von Werder K, Torhoest J, Klijn KGM, Lamberts SWJ. Somatostatin receptors in human endocrine tumors. Cancer Res 1987;47:551-558.
48. Rodriguez-Perez F, Albillos A, Groszman RL. Octreotide improves renal function, total exchangeable sodium, and peripheral hemodynamics in cirrhotic patients with ascites. Gastroenterology 1993;104:980A. (Abstract).
49. Ross R. The pathogenesis of atherosclerosis. An update. N Engl J Med 1986;314:488-500.
50. Sabat M, Guarner C, Soriano G, et al. Effect of subcutaneous administration of octreotide on endogenous vasoactive systens and renal function in cirrhotic patients with ascites. Dig Dis Sci 1998;43:2184-2189.
51. Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994;15:555-573.
52. Sakamoto H, Sakamaki T, Kanda T, et al. The somatostatin analog, octreotide, inhibits in vitro outgrowth of smooth muscle cells from canine coronary and carotid atherosclerotic plaque tissues. Res Commun Mol Pathol Pharmacol 1998;101:25-34.
53. Schwartz RS, Topol EJ, Serruys PW, Sangiori G, Holmes DR. Artery size, neointima, and remodeling. Time for some standards. J Am Coll Cardiol 1998;31:2087-2094.
54. Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 1979;48:50-53.
55. Sieber C, Gnadinger M, del Pozo E, Shaw S, Weidmann P. Effect of a new somatostatin analogue SMS 201-995 (Sandostatin) on the renin-aldosterone axis. Clin Endocrinol 1988;28:25-32.
56. Srikant CB, Shen SH. Octreotide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells. Endocrinology 1996;137:3461-3468.
57. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995;80:3267-3272.
58. Tokgozoglu SL, Erbas T, Aytemir K, Akalin S, Kes S, Oram E. Effects of octreotide on left ventricular mass in acromegaly. Am J Cardiol 1994;74:1072-1074.
59. von Essen R, Ostermaier R, Grube E, et al., for the VERAS Investigators. Effects of octreotide treatment on restenosis after coronary angioplasty. Results of the VERAS study. Circulation 1997;96:1482-1487.
60. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988;57:443-478.
61. Yumi K, Fagin JA, Yamashita M, et al. Direct effects of somatostatin analog octreotide on insulin-like growth factor-I in the arterial wall. Lab Invest 1997;76:329-338.